Literature DB >> 9044481

Idiopathic pulmonary fibrosis and pulmonary fibrosis in diffuse systemic sclerosis: two fibroses with different prognoses.

S A Papiris1, P G Vlachoyiannopoulos, M A Maniati, K X Karakostas, S H Constantopoulos, H H Moutsopoulos.   

Abstract

Idiopathic pulmonary fibrosis and diffuse cutaneous systemic sclerosis (dSSc) involve the lung by a fibrotic process. In recent years, there has been increasing awareness that the natural history of these two types of pulmonary fibrosis might be different. The purpose of this study was to compare lung involvement in these two diseases in a prospective fashion in order to address differences in their clinical course. Forty-three consecutive patients, 18 with lone interstitial pulmonary fibrosis (lone IPF) and 25 with dSSc-IPF were evaluated clinically, radiologically and physiologically at the entry into the study and the evolution of their disease was contrasted by survival analysis. Patients with lone IPF compared with dSSc-IPF were characterized by male predominance (p < 0.001), older age at disease onset (p < 0.001), shorter disease duration (p < 0.001), more frequent crackles on auscultation and clubbing (p < 0.001 and p < 0.0001, respectively), more severe dyspnea (p < 0.0001) and more advanced radiological involvement (p < 0.0001). Functional indices presented comparable values and did not reach statistically significant differences except for the values of single breath CO diffusing capacity (p < 0.0001) and the PaO2 (p < 0.01) which was worse in patients with lone IPF. Finally 12 of the 18 patients with lone IPF died in 2.66 +/- 1.18 years from the onset of respiratory symptoms, while none of the dSSc-IPF patients had died 5.6 +/- 4.25 years from the first ever appearance of respiratory involvement (p < 0.001). In conclusion, although the two groups of patients were not at an absolutely comparable stage of their disease, a worse prognosis for patients with lone IPF seems to emerge from this study.

Entities:  

Mesh:

Year:  1997        PMID: 9044481     DOI: 10.1159/000196648

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  9 in total

1.  Lower-lobe shrinkage relative to total lung volume in collagen vascular diseases.

Authors:  M Watanabe; T Igishi; N Burioka; J Kurai; Y Fukuoka; K Kato; A Yamasaki; Y Hasegawa; R Okazaki; E Shimizu
Journal:  Radiol Med       Date:  2010-06-23       Impact factor: 3.469

2.  Outcomes of lung transplantation in patients with scleroderma.

Authors:  Malek G Massad; Charles R Powell; Jacques Kpodonu; Cimenga Tshibaka; Ziad Hanhan; Norman J Snow; Alexander S Geha
Journal:  World J Surg       Date:  2005-11       Impact factor: 3.352

3.  Treating CTDs related fibrotic ILDs by immunosuppressants: "facts and faults".

Authors:  Spyros A Papiris; Konstantinos Kagouridis; Georgia Papadaki; Likurgos Kolilekas; Effrosyni D Manali
Journal:  Lung       Date:  2013-11-12       Impact factor: 2.584

Review 4.  Management of connective tissue diseases associated interstitial lung disease: a review of the published literature.

Authors:  Beth Wallace; Dharshan Vummidi; Dinesh Khanna
Journal:  Curr Opin Rheumatol       Date:  2016-05       Impact factor: 5.006

5.  Centrilobular emphysema combined with pulmonary fibrosis results in improved survival.

Authors:  Nevins W Todd; Jean Jeudy; Sachin Lavania; Teri J Franks; Jeffrey R Galvin; Janaki Deepak; Edward J Britt; Sergei P Atamas
Journal:  Fibrogenesis Tissue Repair       Date:  2011-02-15

6.  CD8+ T lymphocytes in lung tissue from patients with idiopathic pulmonary fibrosis.

Authors:  Zoe Daniil; Panagiota Kitsanta; George Kapotsis; Maria Mathioudaki; Androniki Kollintza; Marilena Karatza; Joseph Milic-Emili; Charis Roussos; Spyros A Papiris
Journal:  Respir Res       Date:  2005-07-24

Review 7.  Interstitial lung disease pathology in systemic sclerosis.

Authors:  Kristine E Konopka; Jeffrey L Myers
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-07-17       Impact factor: 5.346

8.  CD8+ T lymphocytes in bronchoalveolar lavage in idiopathic pulmonary fibrosis.

Authors:  Spyros A Papiris; Androniki Kollintza; Marilena Karatza; Effrosyni D Manali; Christina Sotiropoulou; Joseph Milic-Emili; Charis Roussos; Zoe Daniil
Journal:  J Inflamm (Lond)       Date:  2007-06-19       Impact factor: 4.981

9.  Angiotensin II type 1 and 2 receptors and lymphatic vessels modulate lung remodeling and fibrosis in systemic sclerosis and idiopathic pulmonary fibrosis.

Authors:  Edwin Roger Parra; Aline Domingos Pinto Ruppert; Vera Luiza Capelozzi
Journal:  Clinics (Sao Paulo)       Date:  2014-01       Impact factor: 2.365

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.